Related Experiment Video
Updated: Jun 10, 2026

07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.3K
High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of
Raymond S Traweek1, Heather G Lyu1, Russell G Witt1,2
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Annals of Surgical Oncology
|February 23, 2024
Summary
High social vulnerability is linked to poorer recurrence-free survival in soft tissue sarcoma patients. Addressing social risk factors is crucial for improving outcomes in sarcoma treatment.
Area of Science:
- Oncology
- Socioeconomic Factors in Health
- Surgical Outcomes
Background:
- Social vulnerability is linked to adverse outcomes in various cancers.
- Its impact on soft tissue sarcoma (STS) patients remains understudied.
Purpose of the Study:
- To investigate the association between social vulnerability and oncologic outcomes in patients with extremity and truncal soft tissue sarcoma.
Main Methods:
- A single-institution cohort study analyzed 577 adult patients with primary or recurrent STS.
- Social Vulnerability Index (SVI) was used to categorize patients (low vs. high vulnerability).
- Kaplan-Meier analysis and Cox regression assessed the impact of SVI on overall survival (OS) and recurrence-free survival (RFS).
Main Results:
- Patients with high SVI showed trends toward worse OS (p=0.07) and significantly worse RFS (p=0.016).
- High SVI was independently associated with shorter RFS (HR 1.64, 95% CI 1.06-2.54) but not OS (HR 1.47, 95% CI 0.84-2.56).
- Key demographic and clinical factors were similar between low and high SVI groups.
Conclusions:
- Community-level social vulnerability is independently associated with worse recurrence-free survival in patients undergoing STS resection.
- Patient and community social risk factors should be considered in the management of extremity sarcoma.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

